Dianthus Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:DNTH) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 348.58 M326.08 M577.45 M530.92 M1.25 B1.21 B Total liabilities 19.97 M23 M30.99 M37.52 M45.57 M41.25 M Total equity 328.61 M303.08 M546.45 M493.4 M1.2 B1.17 B Total liabilities & shareholders' equities 348.58 M326.08 M577.45 M530.92 M1.25 B1.21 B Total debt —————— Net debt ——————

News

Dianthus Stock: The C1s Shakeout Strengthens The Bull Case (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Stocks Settle Sharply Lower on Escalating Middle East Tensions

Stocks Resume Decline as Chipmakers and AI Companies Fall

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Stocks Fall on Weakness in Tech and Trucking Companies

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

William Blair reiterates Dianthus stock rating on CIDP trial data